Oral Health Conditions in Patients Under Antiresorptive Therapy Are Comparable to Unexposed During Supportive Periodontal Care

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2023 Sep 15

PMID 37712984

Authors

Antonio Ciardo

Marlinde M Simon

Sinclair Awounvo

Ti-Sun Kim

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate oral health and oral health-related quality of life (OHRQoL) of patients under antiresorptive therapy (ART) during supportive periodontal care (SPC) considering history of medication-related osteonecrosis of the jaw (MRONJ).

Materials And Methods: In this cross-sectional study, 100 patients (50 receiving ART (exposed) and 50 without ART (unexposed)) in regular SPC were enrolled for a clinical oral examination and the evaluation of OHRQoL using the OHIP-G14-questionnaire. History of MRONJ was assessed by anamnesis and reviewing patient records.

Results: There were no statistically significant group differences in age (exposed: 70.00 ± 9.07 versus unexposed: 71.02 ± 8.22 years), sex, distribution of systemic diseases and duration of SPC (on average 8.61 ± 5.73 years). Number of teeth (21.02 ± 5.84 versus 21.40 ± 5.42), DMFT (18.38 ± 3.85 versus 17.96 ± 4.08), probing pocket depth (2.31 ± 0.20 versus 2.38 ± 0.26), clinical attachment level (3.25 ± 0.76 versus 3.46 ± 0.58) and bleeding on probing (15.07 ± 11.53 versus 15.77 ± 13.08) were also not significantly different. The OHIP-G14 sum-score was significantly higher in exposed participants (6.10 ± 6.76 versus 3.62 ± 5.22, p = 0.043). History of MRONJ was prevalent in 8% of patients under ART. Periodontal/peri-implant-related MRONJ were reported in three participants with cancer (n = 1 before and n = 2 after active periodontal therapy). History of MRONJ due to endodontic/restorative reasons was reported in one patient with osteoporosis.

Conclusions: Patients under ART in SPC demonstrated similar clinical periodontal and dental status but lower OHRQoL compared to unexposed (not statistically significant). Patient awareness of the MRONJ-risk and appropriate preventive measures should be ensured.

Clinical Relevance: SPC in osteoporotic patients under ART appeared safe regarding MRONJ, but further investigations on the MRONJ-risk in patients with different risk-profiles are necessary.

Study Registration: clinicaltrials.gov (#NCT04192188).

References

Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B . Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017; 12:CD003188. PMC: 6486151. DOI: 10.1002/14651858.CD003188.pub4. View

Zhou J, Ma X, Wang T, Zhai S . Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016; 27(11):3289-3300. DOI: 10.1007/s00198-016-3654-z. View

OCarrigan B, Wong M, Willson M, Stockler M, Pavlakis N, Goodwin A . Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017; 10:CD003474. PMC: 6485886. DOI: 10.1002/14651858.CD003474.pub4. View

Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen H . Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19(2):558-67. DOI: 10.1200/JCO.2001.19.2.558. View

Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F . Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin Oral Investig. 2021; 26(3):2839-2852. PMC: 8898220. DOI: 10.1007/s00784-021-04261-4. View

Hallmer F, Bjornland T, Nicklasson A, Becktor J, Andersson G . Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118(2):202-8. DOI: 10.1016/j.oooo.2014.05.006. View

Aguirre J, Castillo E, Kimmel D . Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021; 153:116184. PMC: 8743993. DOI: 10.1016/j.bone.2021.116184. View

Miksad R, Lai K, Dodson T, Woo S, Treister N, Akinyemi O . Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16(1):121-32. PMC: 3228058. DOI: 10.1634/theoncologist.2010-0183. View

10.

Sturrock A, Preshaw P, Hayes C, Wilkes S . Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open. 2019; 9(3):e024376. PMC: 6443056. DOI: 10.1136/bmjopen-2018-024376. View

11.

McGowan K, McGowan T, Ivanovski S . Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2017; 24(4):527-536. DOI: 10.1111/odi.12708. View

12.

Hallmer F, Bjornland T, Andersson G, Becktor J, Kristoffersen A, Enersen M . Bacterial diversity in medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; 123(4):436-444. DOI: 10.1016/j.oooo.2016.11.011. View

13.

Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Ambrosini M . Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008; 49(11):2156-62. DOI: 10.1080/10428190802483778. View

14.

Scoletta M, Arata V, Arduino P, Lerda E, Chiecchio A, Gallesio G . Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg. 2013; 71(6):994-9. DOI: 10.1016/j.joms.2013.01.006. View

15.

Diniz-Freitas M, Fernandez-Feijoo J, Diz Dios P, Pousa X, Limeres J . Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report. J Clin Periodontol. 2018; 45(5):570-577. DOI: 10.1111/jcpe.12882. View

16.

Papapanou P, Sanz M, Buduneli N, Dietrich T, Feres M, Fine D . Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018; 89 Suppl 1:S173-S182. DOI: 10.1002/JPER.17-0721. View

17.

Ainamo J, Bay I . Problems and proposals for recording gingivitis and plaque. Int Dent J. 1975; 25(4):229-35. View

18.

OLeary T, Drake R, Naylor J . The plaque control record. J Periodontol. 1972; 43(1):38. DOI: 10.1902/jop.1972.43.1.38. View

19.

Lindhe J, Nyman S . The role of occlusion in periodontal disease and the biological rationale for splinting in treatment of periodontitis. Oral Sci Rev. 1977; 10:11-43. View

20.

Hamp S, Nyman S, Lindhe J . Periodontal treatment of multirooted teeth. Results after 5 years. J Clin Periodontol. 1975; 2(3):126-35. DOI: 10.1111/j.1600-051x.1975.tb01734.x. View